QTTB
Q32 Bio IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$85.46M
P/E Ratio
2.08
EPS
$2.42
Beta
-1.02
52W High
$8.04
52W Low
$1.34
50-Day MA
$5.83
200-Day MA
$3.50
Dividend Yield
—
Profit Margin
55.50%
Forward P/E
—
PEG Ratio
—
About Q32 Bio Inc
Q32 Bio Inc. (QTTB) is an innovative biotechnology company specializing in the development of cutting-edge antibody-based therapies aimed at treating autoimmune diseases and optimizing immune responses. With its proprietary technology platform, Q32 Bio is advancing a diverse pipeline of therapeutic candidates poised to restore immune balance and address critical unmet medical needs. Supported by a highly experienced management team and strategic partnerships, Q32 Bio is strategically positioned to drive meaningful advancements in healthcare, ultimately creating long-term value for shareholders through its commitment to ongoing research and development excellence.
Fundamentals
| Revenue (TTM) | $53.74M |
| Gross Profit (TTM) | $34.58M |
| EBITDA | $17.29M |
| Operating Margin | 85.40% |
| Return on Equity | 125.10% |
| Return on Assets | 13.70% |
| Revenue/Share (TTM) | $4.37 |
| Book Value | $3.27 |
| Price-to-Book | 2.03 |
| Price-to-Sales (TTM) | 1.59 |
| EV/Revenue | 0.977 |
| EV/EBITDA | 1.68 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $16.96M |
| Float | $6.33M |
| % Insiders | 6.52% |
| % Institutions | 65.96% |
Historical Volatility
HV 10-Day
108.55%
HV 20-Day
112.44%
HV 30-Day
122.72%
HV 60-Day
115.17%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($14.33 target)
2
Buy1
HoldData last updated: 5/2/2026